With our new paper just out thought I'd write a brief thread about one of the ways avian influenza virus ('bird flu') adapts to mammals (with a focus on the polymerase).
The natural host of influenza viruses is wild aquatic birds - ducks, geese, gulls, etc.
Flu is very good at jumping into other species, including mammals like pigs, dogs, horses, and of course humans.
Avian influenza cannot generally infect and replicate within mammals very efficiently. Because flu is an RNA virus and mutates very fast, it can quickly pick up adaptations. Sometimes these adaptations are enough to even transmit between mammals.
Although theres a lot we dont understand - we have a good handle on what some of these mutations are, what they do, and why the virus needs them - great article by @kakape here summerising some of the best known adaptations -
One area which the lab of @wendybarclay11 (where I did one of my postdocs) is particularly interested in is adaptation of the influenza polymerase.
The flu polymerase is responsible for making copies of the viruses RNA genome during virus replication.
Influenza is a fairly simple virus - its genome is less than half the size of a coronavirus genome and and 10x smaller than a herpesvirus genome.
To efficiently copy its genome flu therefore takes maximum advantage of the machinery of the cell it has infected.
However, many of these 'host factors' can vary between a bird and a mammal. This can explain why theres sometimes a block to infection in a new host - the factors the virus likes to hijack are wrong (or even missing entirely).
This is true of many viruses.
Avian influenza had long been known to have a problem with its polymerase in mammalian cells - the virus just isnt able to replicate its genome efficiently.
This had been mapped to a single mutation in one of the units of the influenza polymerase (called PB2 E627K)
The lab of @wendybarclay11 went a step further and identified the exact 'host factor' that was different between birds and mammals that resulted in this. A family of proteins called 'ANP32'.
Specifically birds generally express a longer version of ANP32A which avian influenza can use really well. During adaptation to mammals avian flu has to get PB2-E627K in order to use the shorter version of this protein.
This discovery explained a lot of interesting observations about flu - eg, unlike other birds, ostriches and emus only express the 'short version' so are prone to getting the mammalian-like adaptation PB2-E627K (another good reason not to hug a sick emu!) doi.org/10.1128/JVI.01…
So what does ANP32A actually do?
Well... its pretty complicated and we're still learning but its probably regulating the different types of replication flu polymerase can do, and maybe helping properly assemble new infectious genomes doi.org/10.1038/s41586…
So now a little more into the weeds...
PB2-E627K is not the only mammalian adaptation in PB2 seen. the 2009 pandemic is missing it entirely and instead has different mutations.
In fact many PB2 mutations are known to also adapt to mammals
For example, you may remember recent reports of the H5N1 outbreak on a Spanish mink farm - these did not get E627K, but instead got T271A (which was one of the mutations the 2009 pandemic had). Additionally many human infections result in Q591R/K (also in pandemic 2009) or D701N.
So if E627K specifically adapts the polymerase to use the shorter mammalian ANP32A proteins, what do these other mutations do?
Do they do the same thing or something different?
We aimed to answer this question.
Using human or chicken cell lines where ANP32A (+ANP32B in human cells). We saw that (in our hands at least) both Q591R and D701N also appeared to specifically adapt the polymerase to use the short mammalian ANP32 proteins.
T271A, on the other hand, didnt appear to do this.
Whats more we thought we could see an interesting pattern... although in birds only ANP32A can support flu polymerase, in most mammalian species both ANP32A and ANP32B can support it (to some degree)
We saw a bias in preference for mammalian ANP32A vs ANP32B - while E627K really liked ANP32B, D701N (the other most common adaptation) prefered ANP32A proteins.
This was interesting, as lots of mammals have an ANP32 protein that is 'better' at supporting flu - in mice and humans in ANP32A - in most other mammals its ANP32B
We hypothesised this might explain why E627K is so very common in human cases, and lab mouse experiments, but comparatively rarer in other mammalian infections.
To explore this further we took avian influenza viruses (that had had most of thier genes replaced with those from an attenuated lab strain to make them safer to use) and looked how they adapated to human cells missing ANP32A or ANP32B.
We found that while virus quickly picked up E627K in cells expressing ANP32B (control and ANP32A knock out cells). No E627K was detectible when we knocked ANP32B - suggesting E627K is specifically an adaptation biased towards this ANP32 protein.
What does this mean? Well it might suggest that mammalian adapted viruses might still not be optimally adapted to infect humans (and therefore still have a host barrier). Clearly this isnt too major as in 2009 the swine influenza virus than caused the pandemic didnt have E627K...
I should say as well that viral genetics clearly plays a huge role in this - some avian influenza viruses are incompatable with E627K. Its all pretty complex! doi.org/10.1128/JVI.01…
We started this work pre-pandemic (and I errr got a little distracted), but in that time we now have structures of the influenza polymerase/ANP32 complex.
E627K, Q591R/K and D701N all sit fairly close to one another so this makes a lot of sense! doi.org/10.1038/s41586…
with that I just want to thank the Barclay lab and all co-authors for thier help, particularly @Dr_Shepp and Maragaret Lister for helping get this over the line!
For more info highly recommend this review (which I took lots of figures from for the thread) nature.com/articles/s4157…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Our preprint laying out the evidence for molnupiravir associated sequences in global sequencing data is now out! medrxiv.org/content/10.110…
We believe we've seen strong evidence for onwards transmission of molnupiravir-treated viruses including some quite large clusters.
We would strongly urge public health/genomics bodies to investigate these clusters as this has major implications for any continued use of MOV.
in depth thread laying out the totally of evidence from @theosanderson who has been the major driver of all this work
Over the past few months something interesting has happened with the evolution of SARS-CoV-2 - rather than discrete clonal(ish) waves of BA.1, BA.2 and BA.5 we've seen huge diversification of lineages - to explain whats going on we've written a report: virological.org/t/sars-cov-2-e…
First off we've seen continued emergence of 'variant' or 'saltation' lineages - ie lineages with long branch lengths, rooted in older sequences, no genetic intermediates - similar to the origional Alpha, Beta, Gamma and Omicron itself.
However unlike these 'first generation variants' this new batch have all evolved from a BA.2 background - we therefore refer to them as 'second generation variants' - heres an old thread on this.
Examples include BA.2.75, BA.2.3.20, and BJ.1
Monoclonal antibody (mAb) therapies have been one of the most successful and effective treatments against SARS-CoV-2 during the pandemic. However with the emergence of of variants thier effectiveness has gradually diminished with each new wave.
This is exemplified by the most recent batch of variants such as BA.2.75.2, XBB and BQ.1.1 showing resistance to nearly all approved mAbs.
To help navigate this very dense area of the literature we have written an in depth paper (part review, part meta-analysis) summerising the literature on the topic of mAbs and variants. (led by @CoxMacgregor, @robertson_lab & @alecarabo) nature.com/articles/s4157…
First off a PSA - DO NOT touch, handle or attempt to treat suspected sick or dead birds yourself - particularly poultry, waterfowl (ducks, geese, etc) or seabirds. These are VERY dangerous viruses that can infect people and be deadly!
Instead if you suspect wild birds or domestric poultry might be infected either call your vet or approapriate veternary health body (for example Defra in the UK - see advice here). rspca.org.uk/adviceandwelfa…
Similarly do not let pet dogs go near or pick up dead or suspected sick birds. We know the current strain is infecting foxes, and dogs are similarly suspectible to avian flu. nytimes.com/2022/06/18/hea…
With the BA.5 in the rearview mirror in most places I thought I'd do a quick thread on 'whats next for SARS-CoV-2 variants?' (TL:DR - not really sure but probably a BA.2 offshoot?)
First off: BA.2.75 - this is by far the most prevelent new variant out there - its caused a bit of a wave in India but I'm not sure it has the right combination of properties to cause a global wave like BA.5 did..
More likely perhaps is a BA.2.75 sublineage (of which there are many) - BA.2.75.2 is the most prelevent of these and contains several additional potent antigenic mutations on top of normal BA.2.75 (in black).
Surveillence minded folks - worth keeping a close eye on BA.2.75 - lots of spike mutations, probable second generation variant, apparent rapid growth and wide geographical spread... github.com/cov-lineages/p…
Spike mutation-wise its got normal BA.2 mutations + K147E, W152R, F157L, I210V, G257S, G339H, G446S, N460K and reversion of R493Q - none of these individually really flag as that worrying but all appearing together at once is another matter...
...and an old thread on 'what second generation variants are' here - didnt really talk about this at the time but theres now a growing consensus that these could be arising from chronic infections